GeneTex
United States (US)

IGFBP3 recombinant protein

Cat No. GTX65124

Application ELISA, Functional Assay, Apuri, Blocking
Reactivity Human
Species Human
APPLICATION

Application Note

The ED50 as determined by its ability to inhibit IGF-II induced proliferation of MCF-7 is <0.2 mg/ml, in the presence of 15 ng/ml of human IGF-II.

Calculated MW

28.8 kDa. ( Note )
PROPERTIES

Form

Lyophilized powder

Buffer

20 mM HCl

Storage

Reconstitute in water to a concentration of 0.1-1.0 mg/ml. The solution can then be diluted into other aqueous buffers and store at 4ºC for 1 week or –20ºC for future use.

Antigen Species

Human

Expression System

E. coli

Purification


Purity was assessed by SDS-PAGE (≥98%) and by HPLC (≥98%).

Note

For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
TARGET

Synonyms

Growth-hormone-dependant binding protein, Insulinlike Growth FactorBinding Protein3, Growthhormonedependant binding protein, IBP3, Insulin-like Growth Factor-Binding Protein 3, Insulinlike Growth FactorBinding Protein 3

Background

Human IGF-BP3, also known as growth-hormone-dependant binding protein, is a 28.9 kDa cysteine-rich secreted protein. It is the major IGF binding protein present in the plasma of human and animals. In addition to its ability to modulate the activity of IGF-I and IGF-2, IGF-BP3 also exerts inhibitory effects on follicle stimulating hormone (FSH) activity. Decreased plasma levels of IGF-BP3 often results in dwarfism, whereas elevated levels of IGF-BP3 may lead to acromegaly. The expression of IGF-BP3 in fibroblasts is stimulated by mitogenic growth factors such as Bombesin, Vasopressin, PDGF, and EGF. Recombinant human IGF-BP3 is a 28.8 kDa protein consisting of 264 amino acid residues.

Research Area

Package List Price ($)
$ 259